Topics:

Rheumatoid Arthritis

Rheumatoid Arthritis

The FDA has decided will not regulate health apps designed to collect disease information. They're not ready to be useful for rheumatology. Nonetheless, your patients are undoubtedly using them.

Pregnancy outcomes for women taking medications for rheumatic disease offer reassuring information. Also, details about forthcoming labeling changes for medications used during pregnancy, including biologics.

Early treatment is clearly better in RA, but there has not been agreement about the optimal time frame. A new study clarifies the issue.

A Canadian rheumatology research consortium shuts down, leaving behind a long list of reasons to change the way new-drug trials are conducted and managed.

For treating rheumatoid arthritis not responsive to methotrexate, DMARD combinations beat monotherapy but at greater risk, a summary of recent evidence observes. In another, reviewers disagree about triple therapy.

A large study of insurance claims adds to the evidence linking rheumatoid arthritis treatment to the risk of venous thrombosis.

(ACR14) (VIDEO) In tests so far, the infliximab biosimilar BOW015, just approved in India, seems to look about the same to the human immune system as the original. Here, a VP of the company behind BOW015 talks about the realities of seeking approval in the US.

Pages

Subscribe to Rheumatoid Arthritis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.